Iradimed Corp IRMD
We take great care to ensure that the data presented and summarized in this overview for IRADIMED CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IRMD
View all-
Black Rock Inc. New York, NY818KShares$69 Million0.0% of portfolio
-
Nine Ten Capital Management LLC Evanston, IL771KShares$65.1 Million14.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA567KShares$47.8 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny489KShares$41.2 Million0.05% of portfolio
-
Copeland Capital Management, LLC434KShares$36.6 Million0.66% of portfolio
-
Geode Capital Management, LLC Boston, MA266KShares$22.5 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX215KShares$18.1 Million0.0% of portfolio
-
State Street Corp Boston, MA187KShares$15.8 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY150KShares$12.6 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA145KShares$12.3 Million0.02% of portfolio
Latest Institutional Activity in IRMD
Top Purchases
Top Sells
About IRMD
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Insider Transactions at IRMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 11
2025
|
Monty K Allen |
BUY
Exercise of conversion of derivative security
|
Direct |
905
+3.95%
|
-
|
|
Dec 11
2025
|
John Glenn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
714
-7.78%
|
$69,258
$97.38 P/Share
|
|
Dec 11
2025
|
John Glenn CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,812
+16.49%
|
-
|
|
Dec 11
2025
|
John Glenn CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
15,000
-35.72%
|
$1,455,000
$97.67 P/Share
|
|
Dec 11
2025
|
James B Hawkins |
BUY
Exercise of conversion of derivative security
|
Direct |
905
+2.96%
|
-
|
|
Dec 11
2025
|
Hilda Frederique Scharen Guivel |
BUY
Exercise of conversion of derivative security
|
Direct |
905
+9.52%
|
-
|
|
Dec 11
2025
|
Jeff Chiprin Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
309
-31.02%
|
$29,973
$97.38 P/Share
|
|
Dec 11
2025
|
Jeff Chiprin Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
996
+50.0%
|
-
|
|
Dec 09
2025
|
James B Hawkins |
SELL
Open market or private sale
|
Direct |
3,000
-9.45%
|
$288,000
$96.61 P/Share
|
|
Dec 08
2025
|
Roger E. Susi CEO, PRESIDENT, CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
5,000
-0.05%
|
$480,000
$96.83 P/Share
|
|
Dec 07
2025
|
John Glenn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
11,650
-26.5%
|
$1,095,100
$94.57 P/Share
|
|
Dec 07
2025
|
John Glenn CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
31,512
+42.68%
|
-
|
|
Dec 07
2025
|
Monty K Allen |
BUY
Exercise of conversion of derivative security
|
Direct |
1,197
+5.37%
|
-
|
|
Dec 07
2025
|
Hilda Frederique Scharen Guivel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,197
+13.46%
|
-
|
|
Dec 07
2025
|
James B Hawkins |
BUY
Exercise of conversion of derivative security
|
Direct |
1,197
+3.63%
|
-
|
|
Dec 01
2025
|
Roger E. Susi CEO, PRESIDENT, CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
5,000
-0.11%
|
$460,000
$92.65 P/Share
|
|
Nov 24
2025
|
Roger E. Susi CEO, PRESIDENT, CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
5,000
-0.07%
|
$450,000
$90.33 P/Share
|
|
Nov 20
2025
|
James B Hawkins |
SELL
Open market or private sale
|
Direct |
3,000
-1.54%
|
$264,000
$88.26 P/Share
|
|
Nov 18
2025
|
Roger E. Susi CEO, PRESIDENT, CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
5,000
-0.11%
|
$425,000
$85.71 P/Share
|
|
Nov 10
2025
|
John Glenn CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,651
-80.99%
|
$894,684
$84.51 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 48.2K shares |
|---|
| Open market or private sale | 97.8K shares |
|---|---|
| Payment of exercise price or tax liability | 14.1K shares |